SUBSCRIBE
SUBSCRIBE
News   Drug Development

Pfizer Inc. Reports Promising Phase II Data On Lung Cancer Drug, PF-00299804

October 12, 2010 | 
1 min read
Pharma Times -- Pfizer’s investigational agent PF-00299804 has shown an ability to prevent disease progression when given as a first-line treatment in patients with advanced non-small cell lung cancer.
Clinical research Phase II
Pfizer
MORE ON THIS TOPIC
Map with different syringes. Covid 19 and pandemic vaccination concept. Vector illustration
Earnings
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots
October 24, 2025
 · 
2 min read
 · 
Annalee Armstrong
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Cystic fibrosis
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug
October 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
October 23, 2025
 · 
3 min read
 · 
Tristan Manalac
Museum island on Spree river and Alexanderplatz TV tower in center of Berlin, Germany
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
October 22, 2025
 · 
4 min read
 · 
Tristan Manalac